Vaxart says oral H5N1 vaccine candidate VXA-H5-02 delivers 100% survival in ferret challenge study
Bitget2026/10/08 12:41Vaxart reported publication of a peer-reviewed preclinical study on its oral H5N1 avian flu vaccine candidate VXA-H5-02. Results were presented as published findings, not as upcoming conference data. Vaccinated ferrets survived a lethal H5N1 challenge, while unvaccinated animals died, supporting the candidate’s protective potential. Data also showed reduced infection markers and broader immune activity against multiple H5 strains, suggesting possible cross-strain coverage. The program remains preclinical, with no human testing reported for VXA-H5-02. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxart Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080840PRIMZONEFULLFEED9842173) on October 08, 2026, and is solely responsible for the information contained therein.
- Vaxart reported publication of a peer-reviewed preclinical study on its oral H5N1 avian flu vaccine candidate VXA-H5-02.
- Results were presented as published findings, not as upcoming conference data.
- Vaccinated ferrets survived a lethal H5N1 challenge, while unvaccinated animals died, supporting the candidate’s protective potential.
- Data also showed reduced infection markers and broader immune activity against multiple H5 strains, suggesting possible cross-strain coverage.
- The program remains preclinical, with no human testing reported for VXA-H5-02.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
